Why, who and how should perform liver biopsy in chronic liver diseases

World Journal of Gastroenterology

Volumn 14, Issue 21, 2008, Pages 3396-3402

  Sporea, Ioan ^a   Popescu, Alina ^a   Sirli, Roxana ^a  

^a Department of Gastroenterology   (Romania)

Author keywords

Chronic hepatitis; Fibrosis; Liver biopsy; Ultrasound guidance

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL EFFECTIVENESS; ECHOGRAPHY; ELASTOGRAPHY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GOLD STANDARD; GUIDED IMAGERY; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; NEEDLE; PATIENT SAFETY; PERCUTANEOUS LIVER BIOPSY; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SEROLOGY;

EID: 54349094061     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3396     Document Type: Review

References (60)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-2094
2. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47
3. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562
4. Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 2003; 125: 1053-1059
5. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468
6. Fontolliet CH. Rôle de la biopsie dans le diagnostic et le traitement de l'hépatite chronique C. Med Hyg 2001; 59: 2179-2182. Available from: URL: http://www.revmed.ch/ article.php3?sid=21734
7. Everhart JE, Stolar M, Hoofnagle JH. Management of hepatitis C: a national survey of gastroenterologists and hepatologists. Hepatology 1997; 26: 78S-82S
8. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26: 57S-61S
9. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: 196-200
10. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500
11. Rayssiguier R, Bonny C, Abergel A, Ughetto S, Aublet-Cuvelier B, Bommelaer G, Baranger J, Blanchet G, Delteil J, Hautefeuille P, Lapalus F, Ordono B. Pratiques et attentes des medecins generalistes en matiere d'hepatite c dans la region auvergne. Proceedings of Les 25-emes Journees Francophones de Patologie Digestive, Paris, France, Abstract 76. Available from: URL: http://www.snfge.asso.fr/01- bibliotheque/ 0a-resumes-jfpd/2001/lundi/posters/76.htm
12. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Ledinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54
13. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, El-Kamary SS, Sulkowski M, Bass EB. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36: S161-S172
14. Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, Landais P, El Hasnaoui A, Slama A, Blin P, Thibault V, Parvaz P, Munteanu M, Trepo C. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970-1980
15. Laine F, Bendavid C, Moirand R, Tessier S, Perrin M, Guillygomarc'h A, Guyader D, Calon E, Renault A, Brissot P, Turlin B, Deugnier Y. Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology 2004; 39: 1639-1646
16. Ratziu W, Le Calvez S, Imbert-Bismut F, Messous D, Charlotte F, Bonyhay L, Munteanu M, Puynard T. Diagnostic value of biochemical markers (FibroTest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Proceedings of the 54th Annual Meeting of AASLD, 2003, nov. 25-29, Boston, USA. Abstract 729. Hepatology 2003; 38 Suppl 1: 510-511. Available from: URL: http://www3.interscience.wiley.com/cgi-bin/fulltext/1122120/PDFSTART
17. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713
18. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075
19. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002; 9: 128-133
20. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2419-2425
21. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G, Speers D, Jeffrey G. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003; 49: 450-454
22. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39: 222-230
23. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003; 38: 481-492
24. Thuluvath PJ, Krok KL. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Am J Gastroenterol 2006; 101: 1497-1499
25. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713
26. Foucher J, Vergniol J, Castira L, Le Bail B, Chanteloup E, Adhoute X, Darriet M, Bertet J, Couzigou P, de Ledinghen V: Fibrosis evaluation in chronic liver diseases: comparison of FibroScan with liver biopsy, FibroTest, Forns score, APRI, hyaluronan, prothrombin time and AST/ALT ratio. 40-th Annual Meeting of the EASL, April 13-17, 2004, Paris, France
27. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Ledinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350
28. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi M. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42: 838-845
29. Marcellin P, De Ledinghen V, Dhumeaux D, Poupon R, Ziol M, Bedossa P, Beaugrand M: Non-invasive assessment of liver fibrosis in chronic hepatitis B using FibroScan. Poster to 56th Annual Meeting of AASLD, 2005, nov. 11-15, San Francisco, USA
30. Pares A, Caballeria L, Lazaro E, Garcia-Criado MA, Navasa M, Gilabert R. Transient elastography: a new and useful non-invasive method for assessing liver damage progression in primary billiary cirrhosis. Proceedings of the 56th Annual Meeting of AASLD, 2005, nov. 11-15, San Francisco, USA. Abstract 679. Hepatology 2005, 42 Suppl 1: 464A. Available from: URL: http://www3.interscience.wiley.com/cgi-bin/ fulltext/112099834/PDFSTART
31. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45 Suppl 4: IV1-IV11
32. European Association for the Study of the Liver. Consensus statement. EASL: International consensus Conference in hepatitis C. J Hepatol 1999; 26 Suppl: 2S-10S
33. Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med 1979; 139: 667-669
34. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906
35. Guido M, Rugge M. Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis 2004; 24: 89-97
36. Schiano TD, Azeem S, Bodian CA, Bodenheimer HC Jr, Merati S, Thung SN, Hytiroglou P. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005; 3: 930-935
37. Sporea I, Popescu A, Stirli R, Danila M, Strain M. Ultrasound assisted liver biopsy for the staging of diffuse chronic hepatopathies. Rom J Gastroenterol 2004; 13: 287-290
38. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-481
39. Cadranel JF, Rufat P, Degos F. [Practices of transcutaneous liver biopsies in France. Results of a retrospective nationwide study] Gastroenterol Clin Biol 2001; 25: 77-80
40. Adams T, Lewis JH. Percutaneous liver biopsy. Clin Perspectives Gastroenterol 2002; 2: 117-121
41. Muir AJ, Trotter JF. A survey of current liver biopsy practice patterns. J Clin Gastroenterol 2002; 35: 86-88
42. Anonymous-The blue book of the European Board of Gastroenterology. Available from: URL: http://www.gastrohep.com/eums/UEMS1.pdf
43. Vautier G, Scott B, Jenkins D. Liver biopsy: blind or guided? BMJ 1994; 309: 1455-1456
44. Pasha T, Gabriel S, Therneau T, Dickson ER, Lindor KD. Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology 1998; 27: 1220-1226
45. Younossi ZM, Teran JC, Ganiats TG, Carey WD. Ultrasound-guided liver biopsy for parenchymal liver disease: an economic analysis. Dig Dis Sci 1998; 43: 46-50
46. Farrell RJ, Smiddy PF, Pilkington RM, Tobin AA, Mooney EE, Temperley IJ, McDonald GS, Bowmer HA, Wilson GF, Kelleher D. Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs. J Hepatol 1999; 30: 580-587
47. Riley TR 3rd. How often does ultrasound marking change the liver biopsy site? Am J Gastroenterol 1999; 94: 3320-3322
48. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-173
49. de Man RA, van Buuren HR, Hop WC. A randomised study on the efficacy and safety of an automated Tru-Cut needle for percutaneous liver biopsy. Neth J Med 2004; 62: 441-445
50. Lindor KD, Bru C, Jorgensen RA, Rakela J, Bordas JM, Gross JB, Rodes J, McGill DB, Reading CC, James EM, Charboneau JW, Ludwig J, Batts KP, Zinsmeister AR. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996; 23: 1079-1083
51. Gazelle GS, Haaga JR, Rowland DY. Effect of needle gauge, level of anticoagulation, and target organ on bleeding associated with aspiration biopsy. Work in progress. Radiology 1992; 183: 509-513
52. Plecha DM, Goodwin DW, Rowland DY, Varnes ME, Haaga JR. Liver biopsy: effects of biopsy needle caliber on bleeding and tissue recovery. Radiology 1997; 204: 101-104
53. Maharaj B, Bhoora IG. Complications associated with percutaneous needle biopsy of the liver when one, two or three specimens are taken. Postgrad Med J 1992; 68: 964-967
54. Firpi RJ, Soldevila-Pico C, Abdelmalek MF, Morelli G, Judah J, Nelson DR. Short recovery time after percutaneous liver biopsy: should we change our current practices? Clin Gastroenterol Hepatol 2005, 3: 926-929
55. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneons liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437-441.
56. Chevallier P, Ruitort F, Denys A, Staccini P, Saint-Paul MC, Ouzan D, Motamedi JP, Tran A, Schnyder P, Bruneton JN. Influence of operator experience on performance of ultrasound-guided percutaneous liver biopsy. Eur Radiol 2004; 14: 2086-2091
57. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000; 14: 543-548
58. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 11990, 99: 1396-1400
59. Douds AC, Joseph AE, Finlayson C, Maxwell JD. Is day case liver biopsy underutilised? Gut 1995; 37: 574-575
60. Spiezia S, Salvio A, Di Somma C, Scelzi C, Assanti AP, Giannattasio F, Varriale M, Visconti M. The efficacy of liver biopsy under ultrasonographic guidance on an outpatient basis. Eur J Ultrasound 2002; 15: 127-131.